White light fever
PDT: How It Actually Works (And Why Clinics Screw It Up)
TL;DR: PDT creates free radicals that blow up cancer cells. When done properly. Which it often isn’t.
The Basic Mechanism
Photodynamic therapy works by converting topically applied 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) into protoporphyrin IX (PpIX) inside dysplastic keratinocytes. PpIX is a tetrapyrrolic chromophore that strongly absorbs visible light—particularly the Q-band at ~630 nm and Soret band at ~405 nm.
Cancer cells accumulate more PpIX than normal cells: both synthesize heme, but cancer cells have dysregulated pathways with reduced ferrochelatase activity and limited iron availability. When you add ALA (bypassing the rate-limiting step), normal cells quickly convert excess PpIX to heme, while cancer cells can’t keep up—so PpIX accumulates.
When you hit that accumulated PpIX with red light (630 nm), it transitions through excited states (S₀ → S₁ → T₁) and transfers energy to oxygen, generating singlet oxygen (¹O₂) and other reactive species. These radicals trash cellular lipids, proteins, and DNA, leading to apoptosis or necrosis.
The selectivity ratio? A disappointing 3–4× between dysplastic and normal cells. For context, radiation oncology aims for 10×+, and antibiotics often achieve 100×+ selectivity. PDT works mainly because skin tolerates collateral damage well, not because it’s particularly precise.
Why Modern LED Systems Look White
Clinical PDT platforms use multiple wavelengths beyond therapeutic red:
Blue Light (415 nm): Targets PpIX’s Soret band with higher extinction coefficient than the Q-band. Limited penetration (~0.5 mm) but effective for surface lesions and antimicrobial action against C. acnes.
Green Light (520 nm): Intermediate penetration (~1-2 mm), not strongly absorbed by PpIX but useful for vascular modulation and reducing post-treatment inflammation.
Yellow (630+520 nm) and Pink (630+415 nm) Composites: Balance effects across tissue depths and support combined PDT/rejuvenation protocols.
Near-Infrared (835 nm): Doesn’t activate PpIX. Instead works through cytochrome c oxidase to enhance ATP synthesis and tissue repair—classic photobiomodulation.
The red light does the killing; everything else supports healing and tolerability.
Fluorouracil Pre-Treatment: Making Bad Cells Worse
Pre-treating with 5-FU (Efudix/Carac) for days to weeks before PDT isn’t just protocol padding—it’s biochemical warfare:
- Metabolic Priming: 5-FU disrupts DNA synthesis in rapidly dividing cells, forcing them to upregulate heme biosynthesis. More heme pathway activity = more PpIX accumulation when you later apply ALA.
- Better Penetration: 5-FU breaks down stratum corneum integrity, improving ALA diffusion into basal layers where early cancers hide.
- Immune Activation: Creates local inflammation (IL-1, TNF-α) that synergizes with PDT-induced oxidative stress for better clearance.
Result: Higher selectivity ratios, better clearance rates, lower recurrence. The cells are already stressed and metabolically vulnerable when the light hits.
The Immune Angle: Making Invisible Cells Visible
The real problem with early skin cancers isn’t that they’re hard to kill—it’s that your immune system doesn’t recognize them as threats. They look too much like normal cells, lacking the molecular danger signals that trigger immune clearance.
PDT (and treatments like imiquimod) force cells to release damage-associated molecular patterns that scream “HELP!” to the immune system. It’s immunogenic modulation—making precancerous cells appear dangerous enough to warrant attack.
The challenge: making transformed cells visible without triggering autoimmunity or chronic inflammation. Annual low-intensity PDT could theoretically eliminate invisible precancerous changes before they evolve into something unstoppable. Without burning the fuck out of you.
Where Clinics Screw Up
Insufficient Incubation Time: ALA needs 2-3 hours to penetrate, metabolize to PpIX, and achieve selective accumulation. At 30 minutes (like many cosmetic clinics use), you haven’t achieved selectivity—you’re just irradiating everything. Most protocols call for 1-3 hours, with 3 hours standard in Europe.
Leaving Surface ALA On: Any ALA sitting on the skin surface converts to PpIX and creates surface ROS when illuminated. This causes unnecessary pain and inflammation with zero therapeutic benefit. Proper protocol requires gentle removal of surface product before light exposure.
Poor Patient Selection: Using PDT parameters designed for actinic keratoses on healthy skin for “prevention” or “rejuvenation” is essentially controlled burning with minimal benefit.
The technology works when applied correctly. The problem is clinics cutting corners to save time or maximize profit, turning targeted photochemistry into expensive red-light torture.
Bottom Line
PDT is clever biochemistry hobbled by mediocre selectivity and often poor execution. When done right—proper incubation time, surface cleaning, appropriate patient selection—it’s effective for superficial skin cancers and field treatment. When done wrong, it’s expensive pain with minimal benefit.
The 3-4× selectivity ratio means it’s functional but crude. We’re relying on metabolic differences that barely distinguish cancer from normal cells, then hoping the surrounding tissue can afford the collateral damage.
That’s easy to say when you’re holding the light switch instead of lying under it.
offshore westerly 